KINAXO Biotechnologies GmbH has announced that it has received research funding of about € 1 million from the German Ministry for Education and Research (BMBF). This will enable KINAXO to establish a universally applicable technology platform to quantify small molecule-protein interactions in mammalian tissues and cell lines.
Implementation of the new technologies will be supported by two experts, Dr. Lothar Jansch of the Helmholtz Institute in Braunschweig and Dr. Henrik Daub of the Max Planck Institute for Biochemistry in Martinsried.
Klaus Godl, KINAXO’s Head of Research says: "Combining quantitative mass spectrometry with the KinaTorTM technology significantly strengthens our chemical proteomics capabilities. With this new set-up we can immediately distinguish relevant drug-protein interactions from weak binding as well as determine a compound’s affinity without the need of in vitro assays. Having a proven track record as a kinase specialist we will now start to analyse the target profiles of other inhibitor classes such as protease and phosphatase inhibitors as well as drugs that failed in the clinic due to off-target effects."